{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:19Z","timestamp":1761894679268},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.beha.2007.09.008","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T19:56:20Z","timestamp":1204660580000},"page":"797-816","source":"Crossref","is-referenced-by-count":59,"title":["From the bench to the bedside: emerging new treatments in multiple myeloma"],"prefix":"10.1016","volume":"20","author":[{"given":"Constantine S.","family":"Mitsiades","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/jcb.21213","article-title":"Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment","volume":"101","author":"Mitsiades","year":"2007","journal-title":"Journal of Cellular Biochemistry"},{"issue":"5","key":"10.1016\/j.beha.2007.09.008_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccr.2004.10.020","article-title":"Focus on multiple myeloma","volume":"6","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib4","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"21","key":"10.1016\/j.beha.2007.09.008_bib5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.beha.2007.09.008_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428190600821955","volume":"47","author":"Wu","year":"2006","journal-title":"Leukemia and Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"The Hematology Journal"},{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0609.2007.00823.x","article-title":"Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma","volume":"78","author":"Offidani","year":"2007","journal-title":"European Journal of Haematology"},{"issue":"7","key":"10.1016\/j.beha.2007.09.008_bib10","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib13","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/blood.V93.9.3044","article-title":"Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2","volume":"93","author":"Feinman","year":"1999","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2007.09.008_bib14","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.beha.2007.09.008_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin\u2013proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib16","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Research"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib17","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition: a new strategy in cancer treatment","volume":"18","author":"Adams","year":"2000","journal-title":"Investigational New Drugs"},{"issue":"7","key":"10.1016\/j.beha.2007.09.008_bib19","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Research"},{"issue":"24","key":"10.1016\/j.beha.2007.09.008_bib20","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"10.1016\/j.beha.2007.09.008_bib21","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"12 Pt 1","key":"10.1016\/j.beha.2007.09.008_bib22","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/j.beha.2007.09.008_bib23","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2007.09.008_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib25","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib26","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib27","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"18 supplement","key":"10.1016\/j.beha.2007.09.008_bib28","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/jco.2006.24.18_suppl.7521","article-title":"Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009)","volume":"24","author":"Weber","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.beha.2007.09.008_bib29","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2007.09.008_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Roccaro","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2007.09.008_bib31","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2007.09.008_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib33","first-page":"131","article-title":"Lenalidomide and bortezomib in multiple myeloma: Influence on osteoclast","volume":"92","author":"Breitkreutz","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib34","doi-asserted-by":"crossref","first-page":"124A","DOI":"10.1182\/blood.V108.11.405.405","article-title":"Lenalidomide plus bortezomib (Rev-Vel) in relapsed and\/or refractory multiple myeloma (MM):final results of a multicenter phase 1 trial","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib35","first-page":"179","article-title":"Phase 1\/2 study of upfront Rev\/Vel\/Dex in MM: Early results","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib36","first-page":"235","article-title":"Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma","volume":"12","author":"Wang","year":"2007","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"10.1016\/j.beha.2007.09.008_bib37a","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2007-01-066977","article-title":"Toward a new therapeutic backbone in myeloma","volume":"109","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib37b","doi-asserted-by":"crossref","first-page":"1010A","DOI":"10.1182\/blood.V108.11.3539.3539","article-title":"Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angewandte Chemie International Edition in English"},{"issue":"5","key":"10.1016\/j.beha.2007.09.008_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.beha.2007.09.008_bib40","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib41","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","article-title":"The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells","volume":"136","author":"Stapnes","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib42","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib43","first-page":"156","article-title":"Clinical responses in multiple myeloma and waldenstrom's macroglobulinemia with the proteasome inhibitor carfilzomib (PR-171)","volume":"92","author":"Alsina","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2007.09.008_bib45","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/j.beha.2007.09.008_bib46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/10428190500472123","article-title":"Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma","volume":"47","author":"Duus","year":"2006","journal-title":"Leukemia and Lymphoma"},{"issue":"46","key":"10.1016\/j.beha.2007.09.008_bib47","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.0608372103","article-title":"Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90","volume":"103","author":"Sydor","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib48","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2007.09.008_bib49","doi-asserted-by":"crossref","first-page":"6826","DOI":"10.1158\/1078-0432.CCR-06-1331","article-title":"Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma","volume":"12","author":"Francis","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib50","first-page":"109a","article-title":"Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.008_bib51","series-title":"A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM)","author":"Richardson","year":"2006"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib52","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2002-02-0376","article-title":"2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells","volume":"100","author":"Chauhan","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib53","first-page":"692A","article-title":"Novel therapy with 2-methoxyestradiol (2ME2) for the treatment of relapsed and plateau phase multiple myeloma","volume":"102","author":"Rajkumar","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nature Reviews. Cancer"},{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib56","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","article-title":"Molecular sequelae of histone deacetylase inhibition in human malignant B cells","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications","volume":"101","author":"Mitsiades","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib58","doi-asserted-by":"crossref","first-page":"420A","DOI":"10.1182\/blood.V104.11.1503.1503","article-title":"Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed\/refractory multiple myeloma","volume":"104","author":"Richardson","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2007.09.008_bib59","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","article-title":"NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma","volume":"102","author":"Catley","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib60","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib61","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","article-title":"The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance","volume":"66","author":"Maiso","year":"2006","journal-title":"Cancer Research"},{"issue":"24","key":"10.1016\/j.beha.2007.09.008_bib62","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"19","key":"10.1016\/j.beha.2007.09.008_bib63","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib64","first-page":"851","article-title":"Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"1","author":"Hayashi","year":"2002","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib65","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2006.06280.x","article-title":"Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study","volume":"135","author":"Berenson","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib67","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-06-1812","article-title":"A phase I\/II study of arsenic trioxide\/bortezomib\/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma","volume":"13","author":"Berenson","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"42","key":"10.1016\/j.beha.2007.09.008_bib68","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib69","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.V98.9.2853","article-title":"The AKT kinase is activated in multiple myeloma tumor cells","volume":"98","author":"Hsu","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib70","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.onc.1205194","article-title":"Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses","volume":"21","author":"Hsu","year":"2002","journal-title":"Oncogene"},{"issue":"37","key":"10.1016\/j.beha.2007.09.008_bib71","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Mitsiades","year":"2002","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.beha.2007.09.008_bib72","first-page":"3876","article-title":"Cytokines modulate telomerase activity in a human multiple myeloma cell line","volume":"62","author":"Akiyama","year":"2002","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib73","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib74","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts","volume":"109","author":"Gajate","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib75","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2006-10-052845","article-title":"JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells","volume":"110","author":"Kiziltepe","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib76","first-page":"155","article-title":"Perifosine (KRX-0401) plus low dose dexamethasone is active in patients with relapsed and refractory multiple myeloma (MM): Perifosine MM investigator group phase II multicenter study update","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib77","first-page":"155","article-title":"A multicenter phase I\/II trial of perifosine (KRX-0401) + bortezomib in relapsed and refractory multiple myeloma patients previously treated wth bortezomib: Preliminary results","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib78","first-page":"154","article-title":"A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: Preliminary results. Multiple myeloma research consortium (MMRC) trial","volume":"92","author":"Jakubowiak","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib79","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib80","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1365-2141.2002.03429.x","article-title":"FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance","volume":"117","author":"Rasmussen","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib81","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2007.09.008_bib82","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-06-0957","article-title":"CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice","volume":"12","author":"Xin","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib83","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2007.09.008_bib84","first-page":"382","article-title":"Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis","volume":"255","author":"Albrightson-Winslow","year":"1990","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib85","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0192-0561(93)90045-Z","article-title":"Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression","volume":"15","author":"Badger","year":"1993","journal-title":"International Journal of Immunopharmacology"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib86","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.leu.2401336","article-title":"Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma","volume":"13","author":"Rajkumar","year":"1999","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib87","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib88","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","article-title":"Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration","volume":"98","author":"Podar","year":"2001","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2007.09.008_bib89","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1158\/0008-5472.CAN-04-0124","article-title":"Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib","volume":"64","author":"Podar","year":"2004","journal-title":"Cancer Research"},{"issue":"51","key":"10.1016\/j.beha.2007.09.008_bib90","doi-asserted-by":"crossref","first-page":"19478","DOI":"10.1073\/pnas.0609329103","article-title":"The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma","volume":"103","author":"Podar","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.beha.2007.09.008_bib91","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2003-10-3527","article-title":"GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment","volume":"103","author":"Podar","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2007.09.008_bib92","first-page":"5019","article-title":"The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787\/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Research"},{"issue":"1 Pt 1","key":"10.1016\/j.beha.2007.09.008_bib93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1078-0432.CCR-0221-3","article-title":"Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma","volume":"10","author":"Zangari","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib94","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-006-9022-7","article-title":"A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma\u2013NCIC CTG IND.145","volume":"24","author":"Kovacs","year":"2006","journal-title":"Investigational New Drugs"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib95","first-page":"153","article-title":"VEGF-R inhibition with pazopanib (GW786034) is ineffective in pretreated myeloma","volume":"92","author":"Prince","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"13","key":"10.1016\/j.beha.2007.09.008_bib96","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"104","author":"Frost","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2007.09.008_bib97","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","article-title":"Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma","volume":"104","author":"Raje","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2007.09.008_bib98","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Cancer cell"},{"key":"10.1016\/j.beha.2007.09.008_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.22845","article-title":"Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival","author":"Menu","year":"2007","journal-title":"International Journal of Cancer"},{"issue":"19","key":"10.1016\/j.beha.2007.09.008_bib100","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","article-title":"MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo","volume":"12","author":"Hideshima","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib101","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2141.2007.06629.x","article-title":"Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth","volume":"138","author":"Jourdan","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1016\/j.beha.2007.09.008_bib102","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","article-title":"Genetic abnormalities and patterns of antigenic expression in multiple myeloma","volume":"11","author":"Mateo","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2007.09.008_bib103","first-page":"17","article-title":"The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements","volume":"194","author":"Bergsagel","year":"1995","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib104","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V85.2.436.436","article-title":"In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain","volume":"85","author":"Bergsagel","year":"1995","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2007.09.008_bib105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","article-title":"CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications","volume":"25","author":"Treon","year":"2002","journal-title":"Journal of Immunotherapy"},{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib106","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.leu.2404558","article-title":"Rituximab in CD20 positive multiple myeloma","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib107","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/10428190600564803","article-title":"Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma","volume":"47","author":"Zojer","year":"2006","journal-title":"Leukemia and Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2007.09.008_bib108","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/blood-2004-03-0963","article-title":"Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells","volume":"104","author":"Tassone","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2007.09.008_bib109","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-05-1657","article-title":"Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Research"},{"issue":"13","key":"10.1016\/j.beha.2007.09.008_bib110","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1158\/0008-5472.CAN-04-4125","article-title":"Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.beha.2007.09.008_bib111","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/0008-5472.CAN-03-3630","article-title":"Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications","volume":"64","author":"Tai","year":"2004","journal-title":"Cancer Research"},{"issue":"7","key":"10.1016\/j.beha.2007.09.008_bib112","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood-2002-09-2813","article-title":"CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase\/AKT\/NF-kappa B signaling","volume":"101","author":"Tai","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2007.09.008_bib113","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1365-2141.2003.04322.x","article-title":"Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells","volume":"121","author":"Hayashi","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"11-12","key":"10.1016\/j.beha.2007.09.008_bib114","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2119\/2006-00082.Stevenson","article-title":"CD38 as a therapeutic target","volume":"12","author":"Stevenson","year":"2006","journal-title":"Molecular Medicine"},{"issue":"2","key":"10.1016\/j.beha.2007.09.008_bib115","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4049\/jimmunol.155.2.925","article-title":"Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma","volume":"155","author":"Ellis","year":"1995","journal-title":"Journal of Immunology"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib116","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V108.11.3457.3457","article-title":"CS1: A potential new therapeutic target for the treatment of multiple myeloma","volume":"108","author":"Hsi","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib117","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood.V108.11.3503.3503","article-title":"Eradication of tumors in pre-clinical models of multiple myeloma by Anti-CS1 monoclonal antibody HuLuc63: Mechanism of action studies","volume":"108","author":"Rice","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2007.09.008_bib118","first-page":"148","volume":"92","author":"Tai","year":"2007","journal-title":"Haematologica-the Hematology Journal"},{"issue":"11","key":"10.1016\/j.beha.2007.09.008_bib119","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V104.11.286.286","article-title":"Defibrotide (DF) targets tumor-microenvironmental interactions and sensitizes multiple myeloma and solid tumor cells to cytotoxic chemotherapeutics","volume":"104","author":"Mitsiades","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.008_bib120","first-page":"94","article-title":"Efficacy and safety of melphalan, prednisone,thalidomide and defibrotide in relapsed and refractory multiple myeloma patients: Results of a multicenter phase I\/II trial","volume":"92","author":"Palumbo","year":"2007","journal-title":"Haematologica-the Hematology Journal"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T20:46:40Z","timestamp":1684270000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1521692607000746"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.09.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}